das 28 in clinical practice speaker – date – place
Post on 31-Mar-2015
220 Views
Preview:
TRANSCRIPT
DAS 28 in clinical practiceSpeaker – Date – Place
2
DAS 28 in clinical practice
Introduction – Disease activity scoring
DAS 28 components
Formula's
DAS 28 segments
Response criteria
DAS 28 in current clinical practice
Importance of low disease activity
Discussion
Presentation of DAS 28 exercise
3
Introduction Disease Activity Scoring
4
The DAS score
Main reason for introduction of a standardised scoring system for RA disease activity: need for uniformity in the interpretation of RA clinical trial data and individual patient outcomes
DAS was introduced in 1983 (originally, 44 articulations were scored)
DAS 28, apart from other paramaters, scores tenderness and swelling in a limited number of joints
DAS 28 is fast, easy to use and as valid as more comprehensive joint counts
Change in disease activity (DAS) over time compared to baseline allows estimation of response (EULAR response criteria)
Source: www.das-score.nl
5
DAS 28 components
6
Components of DAS 28 scoreJOINTS
SJC
Number of Swollen Joints out of 28 joints: shoulders, elbows, wrists, MCP joints, PI joints and knees
TJC
Number of Tender Joints out of 28 joints
Source: Eular handbook of clinical assessments in RA – Third edition
7
Components of DAS 28 scoreJoint ASSESSMENT TECHNIQUE
Swelling (SJC):
Soft tissue swelling, detectable along the joint margin
Synovial effusion invariably means the joint is swollen
Bony swelling or deformity, or oedema surrounding the joints do not constitute joint swelling
Fluctuation is a characteristic feature of swollen joints
Joint swelling may influence the range of joint movement (for example decreased dorsiflexion of the wrist, or decreased elbow extension). This can be useful in determining the presence of swelling
Source: Eular handbook of clinical assessments in RA – Third edition
8
Components of DAS 28 scoreJoint ASSESSMENT TECHNIQUE
Tenderness (TJC):
Pain in a joint under defined circumstances, including:
Pain at rest with pressure (for example MCP and wrist joints)
Pain on movement (for example shoulders)
From questioning about joint pain
Pressure to elicit tenderness should be exerted by the examiner's thumb and index finger, sufficient to cause 'whitening' of the examiner's nail beds
Source: Eular handbook of clinical assessments in RA – Third edition
9
Components of DAS 28 scoreESR or CRP
ESR (erythrocyte sedimentation rate) in mm/hUnspecific marker of inflammatory processes
Normal range: 1-15 mm/h (slightly higher in women)
Also increased in AID, like RA, or in case of malignancy
Reflects disease activity of the past few weeks
CRP (C-reactive protein) in mg/LSensitive marker of inflammatory processes
Normal range: below 3 mg/L
Less susceptible to disturbing factors than ESR
Better reflects short-term changes
Shorter waiting time for lab result
Source: Eular handbook of clinical assessments in RA – Third edition
10
Components of DAS 28 scoreVisual Analogue Scale (VAS)
Scale of 100 mm
Range: 0-100
Reflects perception by your patient of global disease activity
Source: Eular handbook of clinical assessments in RA – Third edition
11
DAS 28 Formula's Disease activity segmentsResponse criteria
12
Validated formula's depending on availability of data….
DAS 28 ESR 40.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.70*Ln(ESR) + 0.014*VAS
DAS 28 ESR 3 (no VAS)[0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.70*Ln(ESR)]*1.08 + 0.16
DAS 28 CRP 4 (CRP)0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(CRP+1) + 0.014*VAS + 0.96
DAS 28 CRP 3 (CRP, no VAS)[0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(CRP+1)]*1.10 + 1.15
Note: VAS in mm ! (0-100) CRP in mg/L (lab values mostly given in mg/dL)
Source: Eular handbook of clinical assessments in RA – Third edition
13
Linking DAS 28 and DAS 44
The following formula allows to indirectly calculate DAS 28 values from known (historical) DAS (44) values:
DAS 28 = (1,072 x DAS 44) + 0,938
Range DAS: 1-9
Range DAS 28: 2-10
Source: Eular handbook of clinical assessments in RA – Third edition
14
2,6
3,2
5,1
0
1
2
3
4
5
6
7
8
9
10
DA
S 2
8 S
CO
RE
High Activity
Medium Activity
Low Activity
Remission
Validated DAS 28 segments according to disease activity
Therapeutic goal
Source: www.das-score.nl
15
EULAR response criteria
DAS improvement
DAS at endpoint
DAS 28 at endpoint
> 1.2 0.6 – 1.2 ≤ 0.6
≤ 2.4 ≤ 3.2 low
disease activity
Good response
Moderate response
No response
2.4 – 3.7 3.2 – 5.1 medium
disease activity
Moderate response
Moderate response
No response
> 3.7 > 5.1 high
disease activity
Moderate response
No response
No response
Source: Eular handbook of clinical assessments in RA – Third edition
16
EULAR response criteria
The EULAR response criteria are based on attained level of DAS 28 (at endpoint) – corresponding with the discussed disease activity segments (low, medium, high) …
and classify patients as :
good
moderate
or non-responders
depending on the DAS improvement since baseline
Source: Eular handbook of clinical assessments in RA – Third edition
17
DAS 28 in current clinical practice
18
Median DAS 28 score in RA patients per COUNTRY (2005-2006)
Source: Sokka 2007 – Ann Rheum Dis 66; 407-409
Assessment period: Jan 2005-Oct 2006
0,00
0,50
1,00
1,50
2,00
2,50
3,00
3,50
4,00
4,50
5,00
Denmar
k
Finlan
d
Franc
e
Germ
any
Irelan
dIta
ly
Nether
lands
Spain
Sweden UK
SJC 28
TJC 28
DAS 28
19
Median DAS 28 score > 3.2 means…
PROBABLY MORE THAN 50% OF PATIENTS HAVING DAS 28 SCORES OF > 3.2 !!!
Interpretation median DAS 28 scores
20
26%
13%
43%
19%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
High Activity DAS ≥ 5.1
Medium Activity DAS 3.2 < 5.1
Low Activity DAS 2.6 < 3.2
Remission DAS < 2.6
% of RA patients in each DAS 28 segment(2006)
Roche market research – data on file – data collection period: 2006
Undertreated !
21
Severity as perceived by physician compared per DAS 28 – segment (2006)
N = 3.878 patients with disease severity and DAS score stated
486191
427107
406
224
878
304
108 75345
327
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Severe/Terminal
Moderate
Mild
Underestimated
Remission DAS < 2.6
Low activity DAS 2.6-3.2
Med activity DAS 3.2-5.1
High activity DAS > 5.1
19%43%13%26%
Undertreated !
Roche market research – data on file – data collection period: 2006
22
DAS 28 Importance of low disease activity as a therapeutic goal
23
From DAS to DIS
Disease activity
Joint damage
Disability
(1,3)
(2,3)
(1) Smolen 2004 – Ann Rheum Dis 63: 221-225
(2) Scott 2000 – Rheumatology 39: 122-132
(3) Welsing 2001 – Arthritits Rheum 44: 2009-2017
24
From DAS to DIS
Erosions develop in 10-26% of patients with RA within 3 months from onset of the disease
Even "mild" disease activity is still active disease and may be slowly leading to significant joint destruction and disability.
Therefore, the most important aim in RA treatment is remission
Patients need to be monitored every 2-3 months, as long as they do not reach a state of "no evidence of active disease", in order that the switch of therapeutic strategies can be timely
Smolen 2004 – Ann Rheum Dis 63: 221-225
25
“spikes” of disease activity
0
1
2
3
4
5
6
0 3 6 9 12 15 18
Time on therapy
DA
S s
core
21 24
High level of joint destruction
Low level of joint destruction
Adapted from: Grigor C et al. Lancet, 2004;364:263-9
26
Treatment based on DAS28 targeting low disease activity (DAS 28 < 3.2)
Source: www.das-score.nl
27
Linking DAS and Radiological progression
DAS improvement
(DAS 28 at endpoint)
DAS at endpoint
> 1.2 0.6 – 1.2 ≤ 0.6
≤ 3.2 ≤ 2.4
3.2 – 5.1 2.4 – 3.7
> 5.1 > 3.7NON RESPONDERS
RX PROGRESSION
NO RX PROGRESSION
Svensson 2000 – Rheumatology 39: 1031-1036
28
Linking DAS and Radiological progression
29% of patients, classified as responders, had end-point DAS of > 2.4 (corresponding to a DAS 28 of 3.2 according to the EULAR criteria), indicating moderate or high remaining disease activity
In this group, significant X-ray progression occured, while there was no evident progression in the group of responders (71%) having a final DAS lower than 2.4
In other words: response to treatment (good or moderate) is not enough to avoid progression of joint damage. DAS28 values lower than 3.2 should be targeted
Svensson 2000 – Rheumatology 39: 1031-1036
29
MabThera treatment allows to reach those goals…
-2,39
-2,94-3,1
-3,5
-3
-2,5
-2
-1,5
-1
-0,5
0
1st course 2nd course 3rd course
Week 24, n=97
Mea
n D
AS
28 c
han
ge
fro
m
ori
gin
al b
asel
ine
Vs original baseline
Keystone et al. EULAR 2007 – SAT 0012
30
Mea
n c
han
ge
fro
m b
asel
ine
2,31
0,99
1,32
1
0,410,59
0,0
0,5
1,0
1,5
2,0
2,5
Mean change in totalSharp–Genant score
Mean change in joint spacenarrowing score
Mean change in erosionscore
Placebo (n=184) Rituximab 1000 mg x 2 (n=273)
p=0.0046
p=0.0006
p=0.0114
…which is indeed reflected in significantly better RX scores
Patients with initial and at least 1 follow up with linear extrapolation as required
SPC 2007 - Keystone et al. EULAR 2006 – OP 0016
31
Questions or Remarks ?
top related